None
Quote | Orchard Therapeutics plc (NASDAQ:ORTX)
Last: | $16.70 |
---|---|
Change Percent: | 0.3% |
Open: | $16.65 |
Close: | $16.70 |
High: | $16.72 |
Low: | $16.63 |
Volume: | 372,349 |
Last Trade Date Time: | 01/23/2024 03:00:00 am |
News | Orchard Therapeutics plc (NASDAQ:ORTX)
Crescent Energy Company Class A (CRGY) is expected to report $0.21 for Q4 2023 ThredUp Inc. (TDUP) is expected to report $-0.13 for Q4 2023 Wright Investors` Service Holdings Inc (IWSH) is expected to report for Q4 2023 Bridgford Foods Corporation (BRID) is expected to report for Q1 2...
Gene therapy being developed as a one-time treatment to address the underlying cause of the disease by inserting a functional copy of the human IDUA gene into a patient’s own hematopoietic stem cells HURCULES study to enroll 40 patients at clinical sites across the U.S....
Message Board Posts | Orchard Therapeutics plc (NASDAQ:ORTX)
Subject | By | Source | When |
---|---|---|---|
znewcar1: $ORTX 22% v29,3M c.63 f126,689M H.720 ML.3601 | znewcar1 | investorshangout | 01/06/2023 5:44:45 AM |
Holy volume!! Nice to see life again! Long | 1972 | investorshub | 01/06/2023 1:01:26 AM |
Orchard Therapeutics Announces U.S. FDA Clearance of IND | subslover | investorshub | 01/05/2023 1:51:48 PM |
Just watch .. AF up? | kzivann | investorshub | 12/03/2022 12:03:49 PM |
Again, only a matter of time before ORTX | 1972 | investorshub | 06/11/2022 5:39:12 AM |
News, Short Squeeze, Breakout and More Instantly...
Orchard Therapeutics plc Company Name:
ORTX Stock Symbol:
NASDAQ Market:
Crescent Energy Company Class A (CRGY) is expected to report $0.21 for Q4 2023 ThredUp Inc. (TDUP) is expected to report $-0.13 for Q4 2023 Wright Investors` Service Holdings Inc (IWSH) is expected to report for Q4 2023 Bridgford Foods Corporation (BRID) is expected to report for Q1 2...
Gene therapy being developed as a one-time treatment to address the underlying cause of the disease by inserting a functional copy of the human IDUA gene into a patient’s own hematopoietic stem cells HURCULES study to enroll 40 patients at clinical sites across the U.S....
BOSTON and LONDON, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, a global gene therapy leader recently acquired by Kyowa Kirin with th...